How to Vet a Canadian Psychedelic-Therapy Clinic: A Patient's Guide

This guide gives Canadian patients a practical framework for evaluating any psychedelic-assisted therapy clinic before booking, covering medical oversight, prescriber involvement, provincial accreditation, screening rigour, integration support, and the red flags that should end a conversation.

Medically reviewed by Jacque Lovely, RN, MN, MBA, PMP, Reg #74334 on 2026-05-28.

Key takeaways

• No national licence exists for psychedelic-assisted therapy in Canada. Accreditation is provincial, through the relevant College of Physicians and Surgeons.
• Three regulatory tiers apply: off-label ketamine under provincial colleges; Spravato (esketamine) under Janssen Journey certification (TRD-approved); psilocybin and MDMA only through Health Canada approval granted case-by-case and initiated by a physician.
• A prescribing physician must be involved in every legitimate Canadian psychedelic-assisted therapy programme, and there is no nurse-only, therapist-only, or self-administered clinical model.
• Seventeen questions in this guide cover medical leadership, provincial accreditation, monitoring, screening, integration, cost, and continuity of care.
• Red flags include: outcome guarantees, prominent patient testimonials, pressure to commit before clinical assessment, unsupervised or "at-home" psilocybin/MDMA, no medical screening, and misrepresentation of legal status.
• ATMA CENA's clinical team welcomes every question in this guide on the free information call, on the record, before any commitment.

If you are evaluating psychedelic-assisted therapy options, book a free 15-minute information call, and ATMA CENA's clinical team answers all of these questions before you commit to anything.

Why vetting matters more in this field than in most others

Psychedelic-assisted therapy occupies an unusual regulatory position in Canada. Three structural realities make patient diligence more important here than for most healthcare decisions.

Most clinical work is off-label. IM, sublingual, and oral ketamine are off-label psychiatric uses of a Health Canada-approved anaesthetic. Off-label prescribing is legitimate and well-established in Canadian medicine, but it places clinical judgment, screening rigour, and safety infrastructure on the clinic, not on a label-driven monitoring requirement.

Psilocybin and MDMA require case-by-case Health Canada approval. The only legitimate clinical pathway for psilocybin and MDMA in Canada is a physician-initiated request to Health Canada, granted case by case and not guaranteed. Any provider offering psilocybin or MDMA outside that pathway is operating outside the legal clinical framework.

Provider quality is genuinely variable. A provincially accredited non-hospital facility staffed by an anesthesiologist and a psychiatric clinical reviewer is in a different category from a storefront sublingual lozenge clinic with no medical director on-site. Both can legally call themselves a "psychedelic clinic." Patients often cannot tell the difference from a website.

Vetting is not scepticism for its own sake. It is the same diligence you would apply to choosing a surgeon. A clinic that does not want to answer the questions below is itself a data point.

The regulatory trichotomy: what governs Canadian clinics

Understanding the three regulatory tiers helps you ask the right questions.

Pathway	Substance	Regulatory framework	What to ask
Off-label	Ketamine (IM, SL, oral)	Provincial College of Physicians and Surgeons; provincial non-hospital facility accreditation	Provincial accreditation tier for the route (see below); medical director specialty
Health Canada-approved	Esketamine (Spravato intranasal)	Health Canada NOC (May 2020); Janssen Journey certification; label-mandated in-clinic monitoring	Janssen Journey-certified at this specific location?
Physician-initiated Health Canada approval	Psilocybin (Schedule III); MDMA (Schedule I)	Health Canada authorization, case-by-case, physician/NP-initiated	Does your prescribing physician support these applications? What is the application process here?

No clinic can offer psilocybin or MDMA "freely," not now, not under any provincial framework. Any claim to the contrary is a red flag.

Provincial accreditation tiers for off-label ketamine

Provincial accreditation governs the room the medicine is administered in. For parenteral ketamine, the relevant tier by province:

Province	College	Accreditation tier
Ontario	CPSO	OHPIP Level II (IV / moderate sedation); Level III (deep sedation / GA)
Alberta	CPSA	NSHF (Non-Sedation Health Facility) for IV non-sedation
British Columbia	CPSBC	NHMSFAP (Non-Hospital Medical and Surgical Facilities Accreditation Program)
Quebec	CMQ	CMQ provincial out-of-hospital facility framework
Saskatchewan	CPSS	NHTF (Non-Hospital Treatment Facility) for parenteral
Manitoba	CPSM	New CPSM framework, effective January 2026

These accreditation tiers are necessary but not sufficient. They confirm the facility has been inspected for safe IV or parenteral procedures, but they do not on their own guarantee clinical quality. But the absence of provincial accreditation for a clinic offering IV ketamine is a hard signal.

"We are inspected by CPSO" is not the same as "we are OHPIP Level II accredited for IV procedures." Ask specifically.

17 questions to ask before booking

These questions are not a stress test. Reputable Canadian clinics expect them and welcome them. Bring this list to your information call.

Medical leadership and accreditation

1. "What is your medical director's specialty?" Anaesthesiology, psychiatry, and family medicine are all legitimate backgrounds, but the specialty should match the route. An anaesthesiology background fits IV ketamine. A psychiatry background fits Spravato and KAP psychotherapy programmes. Ask for the match.

2. "Are you provincially accredited? Specifically, what is the accreditation tier for your route and province?" For Ontario IV: OHPIP Level II. For Alberta IV: CPSA NSHF. For BC IV: NHMSFAP. For Saskatchewan parenteral: CPSS NHTF. For Manitoba: CPSM (new framework January 2026). For sublingual or oral routes, accreditation requirements differ; ask what applies.

3. "Are you Janssen Journey-certified for Spravato? At which specific locations?" Janssen Journey certification is location-specific, not corporate-wide. A clinic chain may have one certified location and several that are not yet certified.

Substance and route

4. "For off-label ketamine, what is your route?" IM, sublingual, oral, and intranasal each have different pharmacology, safety profile, monitoring requirement, and accreditation implication. A clinic should be able to articulate why their chosen route fits their model.

5. "For psilocybin, access in Canada is case-by-case through Health Canada. Do you support these applications, and what is the prescribing physician's role in the process?" Any answer that involves psilocybin available without Health Canada approval is disqualifying. Legitimate psilocybin access runs through a prescribing physician who submits the request to Health Canada.

6. "For MDMA, access in Canada is case-by-case through Health Canada. Do you support these applications?" Same framework as psilocybin. MDMA offered without Health Canada approval is not legitimate clinical practice in Canada.

Clinical model

7. "What is your three-phase model, covering preparation, dosing, and integration? How is each phase structured?" A clinic should walk you through preparation session counts, dosing-room protocols, and integration timing without hesitation. Vague answers to this question are a signal.

Safety and monitoring

8. "What vitals are monitored during dosing, and is monitoring continuous?" For IV ketamine and Spravato, continuous vitals monitoring during the active phase is standard. For sublingual or oral ketamine, monitoring intensity varies; ask what is measured and when.

9. "Is your team ACLS-certified? Is there a crash cart on premises?" Advanced Cardiac Life Support certification for the clinical team and an on-premises crash cart are baseline expectations for any clinic administering IV or IM ketamine. Ask directly.

10. "What is your allergy and anaphylaxis protocol?" Epinephrine on-premises, written protocol, and regular training cadence.

Screening

11. "What is your screening for personal and family history of psychotic disorders?" Personal history of psychotic disorders is generally an absolute contraindication for psilocybin and MDMA; a first-degree family history is a strong relative contraindication. Any reputable clinic has a clear answer to this.

12. "What is your screening for bipolar disorder, eating disorders, and cardiovascular conditions?" These categories distinguish a comprehensive intake from a perfunctory one. Ask which validated instruments and which clinical interview structure are used.

Licensure

13. "Is your clinical team licensed to practise in [your province]?" Telehealth-only providers operating across provinces must hold provincial licensure for each province they prescribe in. Verify on the relevant College's public register.

Cost and insurance

14. "What is the full programme cost, including intake, preparation, dosing, integration, medication, and monitoring?" Get the complete picture. Total programme cost varies substantially. Partial numbers are a common source of patient surprises.

15. "Do you support prior authorisation submission for Spravato?" For Spravato, prior authorisation submission is substantial administrative work. A clinic that handles it saves weeks. PSHCP, Manulife, Sun Life, and Green Shield are the principal pathways.

Continuity of care

16. "How do you coordinate with my existing therapist or psychiatrist?" Through ATMA CENA's CoCare program, the clinic can partner with your existing therapist if they have the appropriate training and build a service agreement with ATMA CENA. Ask any clinic how their model handles existing therapeutic relationships.

17. "What does aftercare and integration look like? How many sessions, over how long, and is it included or priced separately?" Integration is the third phase of psychedelic-assisted therapy and is not optional clinical work. A clinic that frames integration as "available if you want it" has not absorbed the evidence base. [Goodwin et al. 2022] [Mitchell et al. 2021] [Mitchell et al. 2023]

Red flags: when to end the conversation

Any one of the following should end a conversation, not start a negotiation.

Red flag	Why it matters
Outcome guarantees ("this will cure your depression")	No reputable provider makes these claims. Response rates in the strongest psilocybin TRD evidence (Goodwin 2022 COMP360 25 mg arm) were 37% response, 29% remission at week 3, meaningful but not universal. Outcome promises are a College-level professional-conduct issue.
Prominent patient testimonials	Patient testimonials in healthcare advertising are restricted under most provincial Medicine Acts and College advertising standards. Reputable Canadian clinics do not use testimonials.
Psilocybin or MDMA offered without Health Canada approval	Psilocybin (Schedule III) and MDMA (Schedule I) are accessible in Canada only through Health Canada approval granted case-by-case and initiated by a physician. "At-home" psilocybin or MDMA outside that pathway is outside the legal clinical framework, unambiguously.
No medical screening before booking	Screening exists to prevent harm. A programme that frames comprehensive medical and psychiatric screening as optional is not a clinical programme.
Pressure to commit before clinical assessment	"Limited spots this month" language or sales urgency are commercial tactics from outside healthcare. Clinical decisions belong with a prescribing physician after assessment.
No integration phase	Integration is the third phase of psychedelic-assisted therapy. A clinic offering dosing without structured integration is offering medication administration, not psychedelic-assisted therapy. All published Phase 3 protocols build in structured integration.
Misrepresentation of legal status	Calling psilocybin "legal," calling MDMA "approved in Canada," or implying access without Health Canada approval is factual misrepresentation. Spravato is Health Canada-approved for TRD. Ketamine is approved as an anaesthetic. Everything else is off-label or requires case-by-case Health Canada approval.
Route and accreditation mismatch	A non-anaesthesiology clinic offering IV ketamine without the relevant provincial NSHF/NHMSFAP/OHPIP accreditation is a structural mismatch between route and safety infrastructure.

Public hospital ketamine programmes as a quality benchmark

For patients with treatment-resistant depression who can access them, publicly funded outpatient psychiatric ketamine programmes at Canadian academic hospitals set a useful quality benchmark.

• Edmonton: Misericordia Community Hospital and Grey Nuns Community Hospital operate publicly funded outpatient psychiatric IV ketamine programmes through the Mental Health Care Pathway (AHCIP).
• Vancouver: UBC Hospital / Vancouver Coastal Health operates a publicly funded IV ketamine programme for TRD.

Both programmes are provincially funded, have psychiatric medical leadership, and are embedded in academic teaching hospitals. The standard a reputable private clinic should meet: equivalent clinical infrastructure, even where private clinics differ in throughput, scheduling flexibility, and integration depth.

What a clinic that meets these criteria looks like

A clinic that answers all 17 questions above will share the following without hesitation:

• Named medical director with specialty and provincial licensure, verifiable on the College register.
• Provincial accreditation certificate for the facility and route. Provincial accreditation is a matter of public record.
• A written three-phase model with preparation, dosing, and integration phase counts specified before you sign anything.
• Written safety protocols for monitoring, ACLS, emergency response, and allergy management.
• Transparent total cost for the full programme, not just the first session.
• No outcome promises and no testimonials, consistent with Canadian College advertising standards.
• Correct framing for psilocybin and MDMA: access is case-by-case, physician-initiated, and not guaranteed.

ATMA CENA operates this way at its corporate clinics (Edmonton, Calgary) and across its CoCare member-clinic network. If you want to talk through any of these criteria for your specific situation, book a free information call.

If you are a therapist or prescriber, ATMA CENA's therapist community shares practitioner resources on this work, including how to assess whether a client may be a good fit for psychedelic-assisted therapy.

Frequently asked questions

Is there a national accreditation that covers psychedelic-assisted therapy clinics in Canada?

No. There is no single national licence for psychedelic-assisted therapy clinics. Accreditation is provincial, through the relevant College of Physicians and Surgeons. The applicable tier depends on your province and the route (IV, IM, sublingual, oral, intranasal Spravato). This is one reason patient diligence matters in this field in a way it does not for most other healthcare decisions.

What is the difference between OHPIP, NSHF, NHMSFAP, and NHTF?

They are the provincial accreditation frameworks for non-hospital facilities administering parenteral or sedation procedures. OHPIP is Ontario (CPSO); NSHF is Alberta (CPSA) for non-sedation IV; NHMSFAP is BC (CPSBC); NHTF is Saskatchewan (CPSS). Manitoba's equivalent (CPSM) is a new framework effective January 2026. Each governs the room IV or parenteral ketamine is administered in.

Does a clinic need accreditation if it only offers sublingual or oral ketamine?

Accreditation requirements for sublingual and oral protocols differ from IV. The route has a different pharmacokinetic profile and lower acute monitoring requirement, but the clinic should still be able to name which provincial framework governs their model and explain what monitoring is in place.

Is "Janssen Journey-certified" the same as Health Canada-approved?

No. Spravato (esketamine) is Health Canada-approved for treatment-resistant depression as a medication. Janssen Journey is the manufacturer's clinical-training and distribution framework that certifies specific clinic locations to administer Spravato under the label-mandated in-clinic monitoring requirement. Ask about both, as they are different things.

What if a clinic refuses to answer these questions?

That is itself a data point. A clinic confident in its clinical infrastructure welcomes these questions. A clinic that frames them as adversarial is telling you something.

Can I ask to see the accreditation certificate?

Yes. Provincial College accreditation is a matter of public record. Reputable clinics display or provide the certificate on request. The provincial College's public register also lists physician licensure status.

How do I verify a physician's licensure?

Every provincial College of Physicians and Surgeons maintains a publicly searchable register of licensed physicians. Enter the physician's name and confirm their status and province of registration.

What is the difference between off-label ketamine and psilocybin or MDMA in plain language?

Off-label ketamine: a Health Canada-approved medication (as an anaesthetic) used by physicians for an off-label psychiatric indication under Canadian off-label prescribing principles. Legitimate and well-established. Psilocybin or MDMA: substances not approved for clinical use in Canada, but accessible case by case through a physician-initiated request to Health Canada for patients with serious conditions where conventional therapy has failed. Both are legitimate clinical pathways; they sit in different regulatory positions.

How do I report a clinic that is misrepresenting itself?

Complaints about physician conduct go to the relevant provincial College of Physicians and Surgeons. Complaints about advertising of unapproved substances or products go to Health Canada. Complaints about consumer practices go to the provincial consumer protection authority.

Should I trust a brand-new clinic?

Newness alone is not disqualifying, and every accredited clinic was new at some point. But a new clinic must demonstrate the same provincial accreditation, medical leadership, and clinical model that an established clinic does. Lack of accreditation is the disqualifying signal, not lack of operating history.

---

Compliance disclaimer

This article is educational. Psilocybin and MDMA are Schedule III and Schedule I controlled substances in Canada respectively; clinical access in Canada is via Health Canada authorization granted on a case-by-case basis and initiated by a physician. This approval is not guaranteed. Psilocybin authorizations are primarily granted for adults with treatment-resistant major depressive disorder or distress associated with a life-threatening illness. MDMA authorizations are primarily granted for adults with PTSD. Ketamine is a Health Canada-approved anaesthetic; psychiatric use is off-label and regulated by provincial medical regulators. Esketamine (Spravato) is Health Canada-approved for treatment-resistant depression. Provincial accreditation requirements are described as of 2026-05-28 and may change; verify with the relevant provincial College for current requirements. Nothing in this article should be construed as a clinical recommendation for a specific individual or as a regulatory determination about a specific clinic.

---

About the author

Reverdi Darda, RN, BScN, Reg #61707 | CEO & Founder, ATMA CENA

Reverdi Darda, RN is CEO & Founder of ATMA CENA and a Registered Nurse with over three decades of experience in healthcare operations, community engagement, policy development, and strategic planning. A recognized leader in mental health access, Reverdi has dedicated her career to advancing evidence-based treatment models and advocating for policy change that prioritizes effective care. She founded ATMA CENA to expand practitioner and public access to psychedelic-assisted therapy across Canada.

---

Sources

1. College of Physicians and Surgeons of Ontario: Out-of-Hospital Premises Inspection Program (OHPIP): https://www.cpso.on.ca/en/Physicians/Your-Practice/Quality-in-Practice/Practice-Programs/OHPIP
2. College of Physicians and Surgeons of Alberta: Non-Sedation Health Facility (NSHF) Standards: https://cpsa.ca/physicians/standards-of-practice/
3. CPSA: Ketamine Prescribing, Administration and Oversight Expectations (March 2026): https://cpsa.ca/wp-content/uploads/2026/03/CPSA_Ketamine-Guidance_March-2026.pdf
4. College of Physicians and Surgeons of British Columbia: NHMSFAP: https://www.cpsbc.ca/programs/nhmsfap
5. College of Physicians and Surgeons of Saskatchewan: NHTF: https://www.cps.sk.ca/
6. College of Physicians and Surgeons of Manitoba: Accreditation framework (effective January 2026): https://cpsm.mb.ca/
7. Health Canada: Requests for psychedelic-assisted psychotherapy through case-by-case access: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/requests-special-access-program-psychedelic-assisted-psychotherapy.html
8. Health Canada: Spravato Notice of Compliance and Product Monograph (DIN 02499290, updated 2025-05-23): https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98903
9. Goodwin GM, Aaronson ST, Alvarez O, et al. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine, 387(18):1637-1648. PMID: 36322843.
10. Mitchell JM, Bogenschutz M, Lilienstein A, et al. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (MAPP1). Nature Medicine, 27(6):1025-1033. PMID: 33972795.
11. Mitchell JM, Ot'alora GM, van der Kolk B, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (MAPP2). Nature Medicine, 29(10):2473-2480. PMID: 37709999.
12. Dore J, Turnipseed B, Dwyer S, et al. (2019). Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices. Journal of Psychoactive Drugs, 51(2):189-198. PMID: 30917760.

---

Last updated: 2026-05-28. This article is reviewed every six months or when provincial regulatory frameworks change.